Alex Federation
Alex Federation is Co-Founder and CEO at Talus Bio and serves as Executive Officer, Director, and Promoter at Talus Bioscience, Inc. He founded Talus Bioscience, a startup still running, and has expertise in bioinformatics, drug discovery, proteomics, gene editing, and data science.
Talus Bio launches Ptarmigan-1, a structure-free AI model for proteome-wide drug discovery
Talus Bio has unveiled Ptarmigan-1, an AI model that claims to enable proteome-wide drug discovery without relying on protein structures, positioning it as a new tool for large-scale drug target identification and screening.
Milad Alucozai spotlights Talus Bio's Ptarmigan-1: a 256-dimensional lookup model that screens trillions of compounds across the regulome and outperforms docking on STAT6 and KRAS G12C
Milad Alucozai describes Talus Bio's Ptarmigan-1, a model that maps proteins and small molecules into a shared 256-dimensional space to enable very fast, large-scale virtual screening across the human regulome without relying on static structures, and reports strong validation on STAT6 and KRAS G12C that suggest the model learned biological signals rather than memorizing data.
Talus Bioscience Raises $11.2M to Develop Drugs Targeting Undruggable Gene-Regulating Proteins
Seattle biotech Talus Bioscience raised $11.2 million in venture capital to advance its drug discovery platform targeting undruggable gene-regulating proteins linked to diseases. Founded in 2020 by Alex Federation and Lindsay Pino, Talus uses its MARMOT platform and machine learning to study transcription factors within living cells.
Talus Bioscience Secures $4.3M in Grants to Advance Gene Activity Drug Discovery Platform
Seattle-based biotech startup Talus Bioscience secured $4.3 million in non-dilutive grants from the Andy Hill Cancer Research Endowment and the SBIR program to advance its drug discovery platform targeting gene activity through transcription factors. The startup, led by CEO Alex Federation and CTO Lindsay Pino, has raised a total of $7 million in venture funding and $7.3 million in grants since its founding in 2020.
Organizations
See all 8-
Talus Bio Executive Officer, Director, Promoter 2024–present, Co-Founder, CEO 2020–present · current
-
SEngine Precision Medicine Lead Bioinformatics Scientist & Pharma Alliance Manager 2020 · past
-
Navigating Cancer Senior Data Scientist 2019–2020 · past
Education
-
Harvard University Ph.D., Chemical Biology · 2011–2015
-
University of Rochester B.S., Chemistry, Cell & Developmental Biology · 2007–2011
